SPH sales revenues for March 2022

“Sopharma” AD (the Company) notifies that for March 2022 the Company recorded a decrease in sales of 23% compared to the same month of the previous year, incl. 10% increase in domestic sales and 55% decrease in export sales. The reduced activity on the main foreign markets is a result of Russia's hostile invasion of Ukraine and consequently the Company's inability to maintain a normal supply of pharmaceutical, OTC and other health-related products to the countries participating in the war.
For the first quarter the revenues from sales of products increase by 29%, incl. 80% increase of sales for the domestic market and 3% decrease in export sales.